Advances in tissue engineering and 3D bioprinting have revolutionized the development of physiologically relevant 3D in vitro cancer models, offering a closer representation of the tumor microenvironment (TME) and enabling high-throughput drug screening.
In a recent study conducted by Carcinotech, we explored whether a 3D-printed lung cancer model developed using our proprietary methodologies could serve as a valuable tool for preclinical research and drug development. This research was first presented at the 2024 European Association for Cancer Research Annual Congress in Rotterdam and subsequently published as a proffered paper in Molecular Oncology.
Goals and Findings
Our novel approach involves developing a patient-derived, 3D-printed lung cancer model. We utilized cells from patient cancer biopsies, including critical TME components, to replicate the TME accurately. Patient tumor biopsies were processed and sectioned into FFPE blocks, with TME assessed using immunofluorescence (IF). Patient-derived cells were cultured and 3D-bioprinted with cancer-specific extracellular matrix components into 96-well plates. After 14 days, we characterized the 3D models' composition, ensuring it mirrored the original tumor. Additionally, we tested immunotherapeutic and standard care treatments, observing response via viability, cytotoxicity, apoptosis assays, and IF microscopy.
Conclusion
Our findings demonstrate that the novel, patient-derived, 3D-printed lung cancer models successfully replicate the TME with high accuracy. Through comprehensive characterization, we confirmed the presence of initial cell types and immune components in the 3D prints, maintaining their integrity 14 days post-printing. Additionally, the models responded effectively to standard and immunotherapeutic treatments, underscoring their potential as platforms for high-throughput drug discovery and screening. These advanced 3D constructs represent a significant step forward in developing novel and combinatorial cancer therapies.
